Skip Navigation

TAKEDA 203 - Bipolar I Maintenance (stable)

Principal Investigator: Jeffrey Rakofsky, MD

Summary: Testing the safety and efficacy of TAK-375 (Ramelteon) at 3 different doses or placebo as an adjunctive therapy of Bipolar I Disorder over a 9 month period.  (sublingual version of Rozerem, a sleep medicine).

Alison Oliver
Senior Researcher